Bullish momentum persists — GSK trades around GBX 1,805 on technical strength

Traders Union
All News
Financial News
GSK rises 0.56% to GBX 1,805.00

Highlights

GSK repurchased 170,000 ordinary shares as part of its £2 billion buyback program, raising treasury shares to 235,772,844 or 5.78% of voting rights.
The company announced acquisition of efimosfermin, a liver-disease treatment asset, from Boston Pharmaceuticals, expanding its pipeline of specialty medicines.
GSK updated its earnings forecast after discussions with the CFO, with investor focus shifting to upcoming trial data and regulatory milestone timings.

Share buyback and asset acquisition shift sentiment with regulatory focus

GSK has completed a buyback of 170,000 ordinary shares as part of its ongoing £2 billion share repurchase program, increasing its treasury shares to 235,772,844 and representing 5.78% of voting rights. The company also announced the acquisition of efimosfermin, a liver-disease treatment asset from Boston Pharmaceuticals. Recent communications included an earnings forecast update following discussions with the CFO, while attention remains on upcoming trial data and regulatory milestone timing.

Bullish momentum confirmed as dynamic supports anchor strong trend

The current price of GSK at GBX 1,805.00 is well above the MA-20 (GBX 1,785.40), MA-50 (GBX 1,667.74), and MA-200 (GBX 1,494.64), confirming bullish momentum across all timeframes. The price also holds comfortably above the Ichimoku Kijun level at GBX 1,713.25, making this area a dynamic support, while the MA-50 (GBX 1,667.74) is the next key support and resistance lies near round levels above today’s high. Momentum remains strong with the MACD showing a "Strong Buy" and ADX indicating a solid trend, but overbought signals emerge from the Bull/Bear Power (BBP), Stochastic RSI, and short-term CCI. The BBP shows persistent buyer dominance intraday, while the RSI is elevated but not extreme. There was no significant gap between the previous close and today’s open. The current price stands near the upper end of today’s range, suggesting strength toward highs amid moderate intraday volatility. The intraday tone is bullish, matching the momentum signals, although some short-term oscillators warn of potential exhaustion.

High upside probability as consolidation precedes potential breakout

For the next five trading days, the adjusted expected price range is GBX 1,780.00 to GBX 1,855.00. The probability of a further price increase is very high (more than 80%), while the probability of a pullback is very low (less than 20%). In the baseline scenario, GSK is likely to fluctuate within this corridor as the current uptrend consolidates. A bullish breakout above GBX 1,855.00 could open the path to new highs if strong momentum persists. However, if the price slips below GBX 1,780.00, a short-term correction toward dynamic supports may unfold before the broader uptrend resumes.

Viktoras Karapetjanc, Senior Analyst at Traders Union, sees GSK’s fundamentals and sentiment positioning the stock for further strength. The recent buyback and strategic acquisition support institutional confidence. Strong macro and technical momentum remain intact, with limited risk of near-term correction. He believes upside is likely as the uptrend consolidates. "With bullish momentum across all timeframes and supportive news flow, I expect GSK to test new highs above GBX 1,855.00 soon."

Previously it was noted that GSK continued its share buyback activity and established a new partnership to advance tuberculosis treatment. The technical outlook described overbought momentum alongside robust trend based on market indicators.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.